All studies
RecruitingPHASE1INTERVENTIONAL

Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML

This phase 1 clinical trial is testing an experimental medicine called AMX-883 for adults with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). It is aimed at people whose condition has returned or has stopped responding to standard treatments. Because this is an early-stage study, the main goal is safety. Doctors want to establish the safest dose, check for side effects, and see how the body handles the drug. Some participants will take AMX-883 on its own, while others will take it alongside a common antifungal tablet called posaconazole to see how the two medicines interact. Taking part involves taking tablets, attending regular hospital visits for health checks and blood tests, and having close monitoring by specialists. The findings will help researchers understand if AMX-883 could become a useful treatment option for blood cancers in the future.

At a glance

Status
Recruiting
Phase
PHASE1
Sponsor
Amphista Therapeutics Ltd
Enrolment target
54
Start
16 Sep 2026
Estimated completion
30 Apr 2029

What is this study about?

Acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) are conditions that affect the bone marrow, where the body produces blood cells. In these conditions, the bone marrow makes abnormal, immature cells instead of healthy blood cells. While standard therapies help many people, these diseases can sometimes return after treatment or fail to respond to routine care. When standard options are exhausted, researchers look for new medicines that can offer hope.

This trial is studying a new drug named AMX-883. It is a 'Phase 1' trial, meaning it is one of the first times this medicine is being given to people. The main purpose of the study is not just to see if the drug works, but to make sure it is safe. Researchers will test different amounts of the drug to discover the best dose, look closely for side effects, and monitor how the medicine is absorbed and cleared by the body.

The study has a few parts. In the first part, people will take AMX-883 alone, and researchers will also check if taking it with food makes any difference. In another part, patients will take AMX-883 together with posaconazole, an antifungal drug often given to leukaemia patients. This will show doctors whether the two medicines can be safely taken at the same time.

Medical trials like this are an essential step in developing new treatments for blood cancer. While taking part cannot guarantee a personal cure, the information gathered from this study will help doctors improve care and develop better treatment programmes for future patients.

Key takeaways

  • Testing a new oral drug called AMX-883 for adults with AML or high-risk MDS.
  • Aimed at patients whose disease has returned or has not responded to standard treatments.
  • The primary goal is to find safe doses and watch carefully for side effects.
  • There are no dummy pills (placebos); every participant gets the active study drug.
  • Taking part is completely voluntary and you can leave the study at any point.

Who may be eligible?

This trial is open to adults aged 18 and older who have been diagnosed with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). It is specifically designed for people whose cancer has either come back after treatment (relapsed) or has not improved with standard therapies (refractory).

To be eligible, you must be in reasonably good general health and able to carry out day-to-day tasks for yourself. You will also need to have functioning kidneys and liver, and you must be able to swallow tablets. Because the effects of this drug on an unborn baby are unknown, women who could become pregnant and men with female partners must agree to use reliable contraception during and after the trial.

You will not be able to take part if you have certain other medical conditions. These include significant heart problems, a family history of specific heart rhythm conditions, active severe infections, or a history of another cancer that needed treatment recently. Your hospital doctor will review your medical history and run tests to see if this study is suitable for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have AML or high-risk MDS that has returned or not responded to routine treatments.
  3. I am well enough to get out of bed and look after my daily needs.
  4. I am able to swallow tablets.
  5. I do not have a history of serious heart rhythm conditions or severe heart disease.
  6. I am happy to use reliable contraception during and after the trial if relevant to me.
Answer every question to see your result.

What does participation involve?

If you join this study, you will take AMX-883 as a tablet by mouth. Depending on which group you are assigned to, you may take it on its own or alongside an antifungal medicine called posaconazole. You will need to visit the hospital clinic frequently, especially in the first few weeks, so doctors can keep a close eye on your health. Visits will involve physical examinations, blood tests, heart rhythm checks (ECGs), and occasional bone marrow tests to see how the leukaemia is responding. You will also be asked to track any symptoms you feel at home. The total time you stay on the trial depends on how your body handles the medicine and whether it continues to benefit you, but you can choose to stop at any point.

Potential risks and benefits

Taking part in an early-stage study has both possible benefits and risks. The potential benefit is that the new medicine might help control your leukaemia when other treatments have stopped working, and you will receive very detailed medical supervision. However, because AMX-883 is a new drug, there may be unexpected side effects, and it might not improve your condition. Before you decide to join, the trial doctor will explain all known side effects and what to look out for. Your participation is entirely voluntary, and you have the right to withdraw from the study at any time without your regular NHS care being affected.

Locations (3)

  • Memorial Sloan-Kettering Cancer Center - Hematology Service MSKCC
    Verified postcode
    New York, United States· Recruiting
  • NEXT Oncology Virginia
    Verified postcode
    Fairfax, United States· Recruiting
  • The Christie NHS Foundation Trust - Christie Hospital
    Verified postcode
    Manchester, United Kingdom· Recruiting

Common questions

What is a Phase 1 clinical trial?

A Phase 1 trial is the earliest stage of human testing for a new drug. Its main aim is to find safe doses and understand any side effects before testing it in larger groups of people.

Will I receive a dummy pill (placebo)?

No. This is an 'open-label' study, which means there is no placebo. Everyone who takes part receives the active study medication.

How do I take the trial medication?

AMX-883 is an oral tablet that you swallow. Your study team will give you precise instructions on how and when to take it, including whether to take it with meals.

Does taking part cost anything?

No. The study drug and all medical tests linked to the trial are free of charge. In many cases, help with travel expenses to and from the hospital may also be available.

Can I leave the study if I change my mind?

Yes. You can leave the trial at any time for any reason. Doing so will not affect your relationship with your doctors or your future care.

How to find out more

Amphista Medical Monitor

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "Phase 1 Open-label Study of AMX-883 Alone in Participants Wi…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.